# OnCo record paper-capivasertib-breast-hr-positive-lancet-oncol-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-capivasertib-breast-hr-positive-lancet-oncol-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-capivasertib-breast-hr-positive-lancet-oncol-2022" ;
  schema:name "Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial"@en ;
  schema:description "Phase 2 or 3 results paper on Capivasertib in HR-positive / HER2-negative breast cancer, in The Lancet Oncology (2022), one of the most cited Europe PMC records with Capivasertib in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-capivasertib-breast-hr-positive-lancet-oncol-2022/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(22)00284-4>, <https://pubmed.ncbi.nlm.nih.gov/35671774/>, <https://europepmc.org/article/MED/35671774> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(22)00284-4> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Howell SJ, Casbard A, Carucci M, et al." ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .